(2,3,4,6-Tetrahydroxy-5-phosphonooxycyclohexyl) dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2,3,4,6-Tetrahydroxy-5-phosphonooxycyclohexyl) dihydrogen phosphate
• 化学式: C₆H₁₄O₁₂P₂
• 分子量: 340.12
• InChiKey: PUVHMWJJTITUGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  214
• 氢给体数：
  8
• 氢受体数：
  12

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING CANCER<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU CANCER
  申请人：UNIV CALIFORNIA

  公开号：WO2019067543A1

  公开（公告）日：2019-04-04

  The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present dislcsoure also provides methods oadministering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

  本公开涉及能够穿透血脑屏障以调节EGFR酪氨酸激酶活性的化合物。该公开进一步涉及治疗胶质母细胞瘤和其他EGFR介导的癌症的方法。该公开还涉及治疗已确定在抑制剂存在下具有改变葡萄糖代谢的胶质母细胞瘤和其他EGFR介导的癌症的方法。本公开还提供了向受试者施用葡萄糖代谢抑制剂和细胞质p53稳定剂的方法。
• [EN] INHIBITORS OF PI3 KINASE<br/>[FR] INHIBITEURS DE LA PI3 KINASE
  申请人：CT NAC INVESTIGACIONES ONCOLOGICAS CNIO

  公开号：WO2011089400A1

  公开（公告）日：2011-07-28

  There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了式（I）的化合物，其中A1、A4、A4a、A5、B1、B1a、B2、B2a、B3、B3a、B4、B4a和R3的含义如描述中所给，并且其药学上可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白激酶或脂质激酶（例如PI3-K和/或mTOR）的疾病中非常有用，特别是在癌症或增生性疾病的治疗中。
• [EN] IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZO[2,1-B][1,3,4]THIADIAZOLE
  申请人：CT NAC DE INVESTIGACIONES ONCO

  公开号：WO2010112874A1

  公开（公告）日：2010-10-07

  There is provided compounds of formula (I): wherein R1, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K) is desired and/or required, and particularly in the treatment of cancer.

  提供了以下式(I)的化合物：其中R1、R2和R3的含义如描述中所示，以及其药学上可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白激酶或脂质激酶（例如PI3-K，特别是I类PI3K）的疾病中非常有用，特别是在癌症治疗中。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2010029082A1

  公开（公告）日：2010-03-18

  The present invention relates to a compound of formula (I) (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及一种式（I）（I）的化合物或其盐，其中取代基如描述中所定义，以及所述化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。
• 2-Carboxamide Cycloamino Ureas
  申请人：FAIRHURST Robin Alec

  公开号：US20110003786A1

  公开（公告）日：2011-01-06

  The present invention relates to compounds of formula I and salts thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。